Arrakis
Arrakis Therapeutics is a biopharmaceutical company pioneering RNA-targeted small molecules (rSMs) as a new class of genetic medicines. Its rSM platform enables orally available small molecules to bind RNA and modulate previously undruggable biological pathways, with an industrialized discovery toolkit spanning multiple modalities. The lead proprietary program targets Type 1 Myotonic Dystrophy (DM1) at the root cause of the disease, alongside a pipeline of proprietary and partnered programs. A GV (Google Ventures) portfolio company in the life-sciences sector, Arrakis was added to the API Evangelist network as a company profile; it publishes a corporate and scientific website but no public developer API surface.
Arrakis is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Pharmaceuticals, and RNA.
Arrakis’ developer surface includes engineering blog, support, and 3 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Company 3
The organization behind the API